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Abstract 
Background: Previous studies suggested that alterations in serum cortisol and DHEA-S levels may 
play a role in the pathophysiology of schizophrenia. Imbalance in serum cortisol and DHEA-S levels 
may be related to responsivity to antipsychotic treatment. 
Aim: To compare serum cortisol and DHEA-S levels between patients with schizophrenia and 
healthy controls and to evaluate their association with psychopathology in schizophrenic patients 
with different response to antipsychotic treatment. 
Material and Methods: This clinical prospective study included 60 patients with schizophrenia and 
40 healthy age and sex matched controls. All patients experienced an acute exacerbation of the 
illness (PANSS: P1 and P3 ≥ 4). Clinical evaluation of patients was performed using the Positive and 
Negative Symptom Scale. A questionnaire for socio-demographic and clinical data collection was 
used. For the purposes of the study, the examined group was divided in two subgroups: responders 
and nonresponders. Serum cortisol and DHEA-S levels were measuredat baseline in all participants 
and after 3 and 6 weeks of the antipsychotic treatment in patients with schizophrenia. 
Results: Patients with schizophrenia had significantly higher serum cortisol and DHEA-S levels 
comparedwith control group. Responders had significantly higher serum cortisol and DHEA-S levels 
compared with nonresponders. Responders group had significant correlation between serum cortisol 
and PANSS positive scale score as well as between hostility and serum DHEA-S.  
Conclusion: Elevated serum cortisol and DHEA-S levels may play a role in the pathophysiology of 
schizophrenia. Serum cortisol and DHEA-S are associated with psychopathology in schizophrenic 
patients with different response to antipsychotic therapy. 
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Introduction 
Hypothalamic-pituitary-adrenal (HPA) axis 
abnormalities play a key role in the etiology 
and pathogenesis of severe psychiatric disor-
ders [1]. The neuroendocrinological system, 
particularly the HPA axis, has been a focus of 
interest for neurobiological studies aiming at elu-
cidating the cause of schizophrenia [2]. HPA axis 
abnormalities may cause an increase in the base-
line cortisol level [3]. It has been demonstrated 
that serum baseline cortisol levels are increased 
in patients with schizophrenia [2–9]. However 
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there are also other studies with contrary fin-
dings [10–11].  
Recently there has been increased interest 
in the role of dehydroepiadrosterone (DHEA) 
which, in its sulfated form (DHEA-S) is the 
most abundant in humans [12]. It is considered 
both a neurosteroid, being produced in the brain, 
as well as a neuroactive steroid, produced in the 
adrenals and gonads and having its effect on 
the brain [13]. Dehydroepiadrosterone sulfate 
(DHEA-S) is a neuroactive steroid interacting 
with N-methyl D-aspartate (NMDA) and gam-
ma-aminobutyric acid (GABA) receptors [14]. 
Previous studies investigating DHEA-S blood 
levels in patients with schizophrenia have de-
monstrated elevated DHEA-S levels [3, 15–16], 
no different [10, 17] and decreased levels [18] 
in schizophrenia patients compared to healthy 
controls. The inconsistencies in published fin-
dings may be due to wide clinical polymer-
phism, small sample sizes, or differences in the 
age and duration of illness of patients enrolled 
in the studies [19].  
Previous studies have suggested that alte-
rations in cortisol and DHEA-S levels may play a 
role in the pathophysiology of schizophrenia 
[3, 16, 20–23]. Serum cortisol and DHEA-S le-
vels may be used as a biological marker for the 
diagnosis of schizophrenia; however, further 
studies with larger sample sizes are warranted 
to support this finding [3].  
Many researchers investigated associa-
tion between serum cortisol and DHEA-S le-
vels with psychopathology in patients with schi-
zophrenia. Authors of one study reported that 
serum DHEA-S levels are positively correlated 
with severity of dysphoric mood, positive and 
activation symptoms [18]. They did not find 
correlations between negative symptoms and 
serum levels of DHEA-S similar to the results 
of one other study [17]. On the other hand there 
is a study which reported correlation between 
DHEA-S plasma levels and negative symp-
toms, but not with depressive and anxiety sym-
ptoms [24]. 
In some studies cortisol secretion was 
primarily associated with more severe positive 
symptoms [2, 5, 25], whereas in others it was 
associated with higher ratings of negative sym-
ptoms [7, 17, 26]. It has been suggested that the 
relation between cortisol levels and symptoms 
severity is due to the augmenting effects of cor-
tisol on dopamine activity [27]. 
Authors of one study investigated asso-
ciation between serum cortisol, DHEA-S le-
vels, as well as their molar ratios with PANSS 
dimensions in schizophrenic patients with dif-
ferent response to antipsychotic treatment [19]. 
They suggest that imbalance in serum cortisol 
and DHEA-S may be related to pathophysio-
logical processes in schizophrenia, particularly 
to responsivity to antipsychotic treatment. 
The aim of the study was to compare se-
rum cortisol and dehydroepiadrosterone-sulfate 
levels between patients with schizophrenia and 
healthy control subjects and to evaluate associ-
ation between these hormones and psycho-
pathology in schizophrenic patients with differ-
rent response to antipsychotic treatment.  
 
Material and methods 
In this clinical prospective study by its 
design were included 60 patients with schizo-
phrenia and 40 healthy age and sex matched 
control subjects.  
Examined group consisted of sixty pati-
ents with schizophrenia from both genders; age 
18-50, treated as inpatients or outpatients at the 
University Psychiatry Clinic, Skopje, Macedo-
nia. All patients experienced an acute exacer-
bation of the illness (PANSS: P1-Delusions 
and P3-Hallucinatory behavior ≥ 4). Patients 
who suffered from major physical illness, drug 
or alcohol abuse, epilepsy and other organic 
brain syndromes were not included. All patients 
underwent physical examination and routine la-
boratory tests to rule out physical illness. Clini-
cal evaluation of patients was performed using 
the Positive and Negative Symptom Scale [28]. 
Non-standardized questionnaire was used for 
socio-demographic and clinical data collection.  
For the purposes of this study, the exami-
ned group was divided in two subgroups: 
1. subgroup of subjects suffering from 
schizophrenia classified as responders who had 
no ratings of > 3 on items P1, P2, P3, P5 and 
P6 of the PANSS. 
2. subgroup of subjects suffering from 
schizophrenia who did not meet these criteria 
were defined as nonresponders. 
Control group consisted of forty healthy 
age and sex matched control subjects. All were 
physically healthy and had no personal or 
family history of psychiatric disorder.  
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All participants in the study provided writ-
ten informed consent to participate in this pro-
spective study after having received a detailed 
explanation of the study procedures. The study 
was approved by the Ethics Committee of Me-
dical University in Skopje and the Board of the 
University Clinic of Psychiatry. 
 
Steroid determination 
Serum cortisol and DHEA-S levels were 
measured in the Institute of clinical biochemist-
ry at the Medical University in Skopje, Mace-
donia. Serum samples of cortisol and DHEA-S 
were collected between 8 a.m. and 9 a.m. hours 
after 20 min of rest. All participants were instruc-
ted to abstain from unusual physical activity or 
stress for a period of 24 h prior to blood sam-
pling. Blood samples were collected at baseline 
in all participants and after 3 and 6 weeks of 
the antipsychotic treatment in patients with schi-
zophrenia. Cortisol and DHEA-S levels were 
measured by the IMMULITE 2000, competi-
tive chemiluminescentenzime immunoassay. 
 
 
Statistical analysis 
Several statistical methods have been used 
for the statistical analysis of the data obtained in 
the course of the study: non-parametric methods 
(Chi-square test, Mann-Whitney U test, Fried-
man ANOVA) and parametric methods (t-test 
for independent samples). Correlation between 
parameterswas examined with Spearman Rank 
correlation coefficient. From the multivariate 
methods MANOVA was used. Values of p < 
0.05 were considered statistically significant. 
 
Results 
Patients with schizophrenia had signifi-
cantly higher mean serum cortisol and DHEA-S 
levels in comparison to the control group 
(Table 1). 
 
Table 1 
 
Serum levels of cortisol and DHEA-S in the examined and control group 
Hormone Examined group Control group test p-value 
 Cortisol 555.7 ± 159.8 351.7 ± 172.1 t = 6.07 0.00000 
 DHEA-S 329.5 ± 125.1 167.4 ± 57.5 t = 7.66 0.00000 
t (t-test for independent samples) 
 
The two subgroups of the examined group 
classified as responders and nonresponders did 
not significantly differ between themselves in 
terms of gender (men/women: 29/8 and 15/8 
respectively; Pearson Chi-square = 1.26 df = 1, 
p = 0.26), age (t = 0.34 p = 0.73), marital status 
(Pearson Chi-square = 1.41 df = 2 p = 0.49), 
education (Pearson Chi-square = 4.21 df = 3 
p = 0.24), age of onset of the disorder (Z = 0.15; 
p = 0.88), duration of illness (Z = 0.32; p = 0.75), 
number of relapses (Z = 0.11; p = 0.9), number 
of hospital treatments (Z = 0.68; p = 0.49) and 
the type of antipsychotic agents – typical/atypi-
cal (Pearson Chi-square = 0.86 df = 1 p = 0.35). 
Table 2 shows serum cortisol and DHEA-S 
levels in the subgroup of responders compared 
with the subgroup of nonresponders at baseline 
assessment point. 
 
Table 2 
 
Serum cortisol and DHEA-S levels at baseline in responders and nonresponders 
Hormone Responders 
N = 37 
Nonresponders 
N = 23 
test p-value 
Cortisol 640.6 ± 116.4 419.1 ± 121.2 7.05 0.000000 
DHEA-S 375.6 ± 114.4 255.4 ± 106.2 4.06 0.00014 
 
Across all three assessment points (base-
line, after 3 and 6 weeks) the responders had a 
significantly higher serum cortisol and DHEA-S 
levels compared with nonresponders (MANOVA, 
Hotelling-Lawley test, F = 16.24; df = 6.226; 
p = 0.000).  
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According to the PANSS scores the sub-
group of responders scored significantly higher 
on positive PANSS scale (F = 6.06; df = 158; 
p = 0.017), delusions (F = 7.41; df = 158; p = 
0.009) and suspiciousness (F = 12.509; df = 
158; p = 0.001) compared with the subgroup of 
nonresponders sat baseline. The differences 
between the subgroups according hallucinatory 
behavior, hostility and negative scale were not 
statistically significant. 
The subgroup of responders showed gre-
ater reduction of the PANSS positive and 
PANSS negative scale scores across all three 
assessment points (baseline, after 3 and 6 weeks 
of antipsychotic therapy) than the subgroup of 
nonresponders (Graph 1; Graph 2). 
 
 
Graph 1 – PANSS positive scale scores across three assessment points in responders and nonresponders 
 
 
Graph 2 – PANSS negative scale scores across three assessment points in responders and nonresponders 
 
Correlation between serum cortisol and 
DHEA-S levelswith PANSS scores across all 
three assessment pointsin the two subgroups 
was examined with Spearman Rank Order Cor-
relations. The results of examined correlation 
between serum cortisol levels and PANSS sco-
res in the subgroup of responders indicated sta-
tistically significant correlation between serum 
cortisol and PANSS positive scale score at the 
third assessment point (Table 3). The correla-
tion is negative, accordingly higher serum cor-
tisol levels significantly correlated with lower 
PANSS positive scale score. Investigated cor-
relation between serum DHEA-S levels and 
PANSS scores in theresponders subgroup sho-
wed statistically significant correlation betwe-
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enhostility and DHEA-S level at second asses-
sment point (Table 4). This correlation is posi-
tive, respectively higher serum DHEA-S levels 
are associated with higher hostility scores. 
 
Table 3 
 
Responders – correlation serum cortisol/PANSS third assessment point 
Cortisol-third assessment 
point  
Spearman Rank Order Correlations p-value 
PANSS – delusions -0.25 > 0.05 
PANSS – hallucinatory 
behavior 
-0.086 > 0.05 
PANSS – suspiciousness /  
PANSS – hostility  0.05 > 0.05 
PANSS – positive scale -0.35 <0.05 
PANSS – negative scale -0.022 > 0.05 
 
Table 4 
 
Responders – correlation serum DHEA-S/PANSS second assessment point 
DHEA-S second assessment 
point  
Spearman Rank Order Correlations p-value 
PANSS – delusions -0.2 > 0.05 
PANSS – hallucinatory 
behavior 
0.29 > 0.05 
PANSS – suspiciousness 0.16 > 0.05 
PANSS – hostility 0.38 <0.05 
PANSS – positive scale 0.21 > 0.05 
PANSS – negative scale 0.11 > 0.05 
  
Examined correlation between serum cor-
tisol and DHEA-S levels with PANSS scores 
across all three assessment points in the sub-
group of nonresponders showed statistically sig-
nificant correlation between cortisol and item 
delusions from the PANSS positive scale at the 
baseline (R = 0.5; p < 0.05). This correlation is 
positive, respectively higher serum cortisol levels 
are associated with higher scores for delusions. 
Investigated correlation between serum DHEA-
S levels and all PANSS item scores in this sub-
group did not show statistically significant cor-
relation between them across all three asses-
sment points. 
 
Discussion 
Recently, studies on schizophrenia have 
increasingly focused on potential causative fac-
tors, such as structural and functional brain ab-
normalities. The assumption that alterations in 
cortisol and DHEA-S levels may have a role in 
changes in clinical presentation of several neu-
ropsychiatric disorders, including schizophre-
nia, has been emphasized [3]. 
Our study showed that plasma cortisol le-
vels were significantly elevated in the group of 
patients with schizophrenia compared with con-
trols, which is in agreement with the results of 
most of the studies [2–9]. However there arestu-
dies reporting no significant differences between 
the schizophrenic patients and healthy controls 
in terms of cortisol levels [10, 29], as well as lo-
wer cortisol levels in patients with schizophrenia 
[11]. 
Examined serum DHEA-S levels in this 
study showed statistically significant higher le-
vels in patients with schizophrenia compared to 
control subjects, which is in agreement with the 
results of most of the studies [3, 15, 16]. In cont-
rast, some other studies found decreased serum 
DHEA-S levels [18] and no different [10] in schi-
zophrenia patients compared to healthy controls. 
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Our results showed that elevated serum 
cortisol and DHEA-S levels in patients with 
schizophrenia may play a role in the pathophy-
siology of schizophrenia.  
Studies evaluating theassociation between 
serum cortisol and DHEA-S levels with psycho-
pathology in patients with schizophrenia pre-
sent a variety of results. Authors of some 
previous studies found positive correlation bet-
ween cortisol levelsand negative symptoms [7, 
17, 26, 30]. In contrast, some other studies 
found a correlation between serum cortisol and 
positive symptoms [2, 5, 25, 31]. It has been 
suggested that the relation between cortisol le-
vels and symptom severityis due to the aug-
menting effects of cortisol on dopamine acti-
vity [27]. Authors of one study did not find 
significant correlation between serum cortisol 
and DHEA-S levels with symptom dimensions 
assessed with the PANSS [9]. Authors of other 
study referred positive correlation between serum 
DHEA-S levels and severity of dysphoric mood, 
positive and activation symptoms [18]. Some 
previous studies found no correlation between 
serum DHEA-S levels and negative symptoms 
in schizophrenia [17, 18]. On the other hand, 
authors of one study reported that changes in 
DHEA-S levels significantly correlated with 
total PANSS, negative and general PANSS [24]. 
Authors of one study investigated serum 
cortisol and DHEA-S levels in two groups of 
schizophrenia patients divided according to their 
responsivity to antipsychotic treatment [19]. 
Their results indicate that responders had sig-
nificantly higher basal levels of cortisol and 
DHEA-S compared with nonresponders. They 
also examined correlation between changes in 
serum values of cortisol and DHEA-S with 
changes in PANSS dimensions. They demon-
strated that among responders increased serum 
DHEA and cortisol concentrations significantly 
correlated with improvement in activation and 
PANSS total score. Reduction over time of 
PANSS total scores in their study showed sig-
nificant association with increased DHEA-S le-
vels. Among nonresponders no significant cor-
relation was observed between changes in any 
hormonal measures and symptom severity accor-
ding to this study.  
Our study evaluated serum cortisol and 
DHEA-S levels and their association with psy-
chopathology in schizophrenic patients with 
different response to antipsychotic treatment. 
The results showed that across all three asses-
sment points (baseline, after 3 and 6 weeks) the 
responders had a significantly higher serum 
cortisol and DHEA-S levels compared with non-
responders which isin agreement withthe re-
sults of authors of one study [19]. These results 
indicate that elevated serum cortisol and DHEA-S 
levels in patients with schizophrenia may be 
related to responsivity to antipsychotic treatment. 
According to the PANSS scores respon-
ders scored significantly higher on positive 
PANSS scale, delusions and suspiciousnes-
scompared with nonresponders which coinci-
ded with the results of other study [19]. In our 
study responders showed greater reduction of 
the PANSS positive and negative scale scores 
across all three assessment points compared with 
nonresponders. Authors of one other study sho-
wed that responders had greater reduction in 
the PANSS total score than nonresponders [19]. 
Examined association between serum 
cortisol and DHEA-S levels with psychopatho-
logy in responders subgroup in our study sho-
wedsignificant correlation between serum cor-
tisol and PANSS positive scale score as well as 
statistically significant correlation between hosti-
lity and serum DHEA-S.  
We investigated the correlation between 
serum cortisol and DHEA-S with psychopatho-
logy in the subgroup of nonresponders showed 
statistically significant correlation between serum 
cortisol and delusions and no significant corre-
lation between serum DHEA-S levels and psy-
chopathology in this subgroup. 
Our results suggested that serum cortisol 
and DHEA-S levels are associated with differ-
rent schizophrenia symptoms in patients with 
schizophrenia according to their responsivity to 
antipsychotic treatment. 
Limited number of studies that investiga-
ted the correlation between serum cortisol and 
DHEA-S levels with psychopathology in pati-
ents with schizophrenia according to their res-
ponsivity to antipsychotic therapy is a reason 
for required similar future researches.  
 
Conclusions 
  Serum cortisol and DHEA-S levels 
were significantly elevated in the group of pa-
tients with schizophrenia compared with controls. 
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  The subgroup of responders had a sig-
nificantly higher serum cortisol and DHEA-S 
levels compared with the subgroup of nonres-
ponders. 
  Responders scored significantly higher 
on positive PANSS scale, delusions and suspi-
ciousness compared with nonresponders. 
  Responders showed greater reduction 
of the PANSS positive and negative scale sco-
res across all three assessment points compared 
with nonresponders. 
  The responder’s subgroup demonstra-
ted significant correlation between serum cor-
tisol and PANSS positive scale score as well as 
between hostility and serum DHEA-S level. 
  The subgroup of nonresponders had sig-
nificant correlation between serum cortisol and 
delusions and no significant correlation between 
serum DHEA-S levels and psychopathology. 
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Voved: Dosega{nite studii uka`uvaat 
deka alteraciite na serumskite koncentra-
cii  na  kortizol  i  DHEA-S  mo`e  da imaat  
 
uloga vo patofizologijata na {izofreni-
jata. Naru{uvaweto na serumskite koncen-
tracii na kortizol i DHEA-S mo`e da e aso-
cirano so odgovorot na antipsihoti~niot 
tretman. 
Cel: Da se sporedat serumskite kon-
centracii na kortizol i DHEA-S me|u pa-
cienti so {izofrenija i zdravi kontroli i 
da se evaluira nivnata asociranost so psi-
hopatologijata kaj pacientite so {izofre-
nija so razli~en odgovor na antipsihoti~-
niot tretman. 
Materijal i metodi: Ovaa klini~ka 
prospektivna studija vklu~i 60 pacienti so 
{izofrenija i 40 zdravi kontroli soodvet-
ni po pol i vozrast. Site pacienti manifes-
tiraa akutna egzacerbacija na bolesta 
(PANSS: P1 i P3 ≥ 4). Klini~kata evaluacija 
na pacientite be{e sprovedena so PANSS. 
Se koriste{e i pra{alnik za sociodemo-
grafski i klini~ki podatoci. Za celite na 
studijata, ispituvanata grupa be{e podelena 
vo dve podgrupi: ispitanici so pozitiven i 
ispitanici so negativen odgovor na tretma-
not. Serumskite koncentracii na kortizol 
i DHEA-S bea odreduvani na po~etokot na 
studijata kaj site ispitanici i po 3 i 6 неде-
ли od antipsihoti~niot tretman kaj pacien-
tite so {izofrenija. 
Rezultati: Pacientite so {izofre-
nija imaa zna~ajno povisoki serumski kon-
centracii na kortizol i DHEA-S vo spored-
ba so kontrolnata grupa. Ispitanicite so 
pozitiven odgovor imaa zna~ajno povisoki se-
rumski koncentracii na kortizol i DHEA-S 
vo sporedba so ispitanicite so negativen 
odgovor. Kaj ispitanicite so pozitiven odgo-
vor ima{e zna~ajna korelacija me|u serum-
skiot kortizol i vkupniot skor na PANSS 
pozitivnata skala, kako i me|u hostilnosta 
i serumskiot DHEA-S. 
Zaklu~ok: Zgolemenite serumski kon-
centracii na kortizol i DHEA-S mo`e da 
imaat uloga vo patofiziologijata na {izo-
frenijata. Serumskite kortizol i DHEA-S 
se asocirani so psihopatologijata kaj paci-
entite so {izofrenija so razli~en odgovor 
na antipsihoti~niot tretman. 
 
Klu~ni zborovi: {izofrenija, kortizol, DHEA-S, 
psihopatologija, pozitiven odgovor, negativen 
odgovor.
 
